Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBT (2016 - 2025)

Historic EBT for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$67.3 million.

  • ImmunityBio's EBT rose 2150.74% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 4069.04%. This contributed to the annual value of -$413.6 million for FY2024, which is 2915.73% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's EBT is -$67.3 million, which was up 2150.74% from -$92.3 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's EBT peaked at -$59.2 million during Q4 2024, and registered a low of -$233.5 million during Q4 2023.
  • For the 5-year period, ImmunityBio's EBT averaged around -$108.1 million, with its median value being -$95.6 million (2023).
  • As far as peak fluctuations go, ImmunityBio's EBT crashed by 11557.83% in 2023, and later surged by 7465.07% in 2024.
  • Over the past 5 years, ImmunityBio's EBT (Quarter) stood at -$91.6 million in 2021, then fell by 18.28% to -$108.3 million in 2022, then plummeted by 115.58% to -$233.5 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then decreased by 13.74% to -$67.3 million in 2025.
  • Its EBT stands at -$67.3 million for Q3 2025, versus -$92.3 million for Q2 2025 and -$129.9 million for Q1 2025.